Mabwell Receives FDA IND Clearance for Novel Autoimmune Disease Antibody 9MW5211

Mabwell Receives FDA IND Clearance for Novel Autoimmune Disease Antibody 9MW5211

By, Admin 9 May 2026

Mabwell announced that the US Food and Drug Administration has cleared the Investigational New Drug (IND) application for 9MW5211 to begin clinical studies in inflammatory bowel disease (IBD).

At the same time, clinical trial applications for multiple indications, including IBD and multiple sclerosis (MS), have also been accepted for review by National Medical Products Administration.

According to the company, 9MW5211 is currently the world’s first clinical-stage drug candidate directed against its specific target.

A Novel Approach to Autoimmune Disease Treatment

9MW5211 is a highly specific antibody developed to selectively target pathogenic immune cells involved in autoimmune disease progression.

Autoimmune diseases occur when the immune system mistakenly attacks healthy tissues, leading to chronic inflammation and tissue damage.

The therapy is designed to:

  • Identify abnormal immune cells
  • Selectively deplete disease-driving cells
  • Interrupt harmful immune cascades
  • Reduce inflammation and disease progression

According to Mabwell, the target molecule is specifically expressed on pathogenic immune cells linked to abnormal immune activation.

Engineered for Greater Precision and Safety

The company stated that multiple rounds of molecular engineering optimization were used to improve:

  • Target selectivity
  • Binding specificity
  • Pathogenic cell depletion efficiency

Mabwell believes the antibody’s mechanism could potentially:

  • Deliver deeper disease remission
  • Reduce off-target immune effects
  • Support extended dosing intervals
  • Improve patient compliance and quality of life

The company also noted that minimizing non-specific binding may help improve the therapy’s overall safety profile.

Positive Preclinical Data Supports Advancement

Preclinical studies reportedly demonstrated promising therapeutic activity across multiple autoimmune disease mouse models. In addition:

  • Safety evaluations in cynomolgus monkey studies showed a favorable safety profile
  • Additional clinical applications for other autoimmune indications are being advanced

The company sees potential for the therapy across several immune-mediated diseases beyond IBD and MS.

Rising Burden of Inflammatory Bowel Disease

Inflammatory bowel disease includes two major chronic gastrointestinal disorders:

  • Ulcerative Colitis
  • Crohn's Disease

IBD prevalence continues to increase globally. According to epidemiological estimates cited by the company:

  • Global IBD cases increased from 5.9 million in 2019 to 7 million in 2023
  • Cases are projected to reach 11.5 million by 2032
  • Expected CAGR from 2023–2032 is approximately 5.6%

The growing patient population continues to drive demand for more targeted and durable therapies.

Multiple Sclerosis Represents Another Major Opportunity

Multiple Sclerosis is another key indication being explored for 9MW5211. MS is characterized by immune-mediated damage to the protective myelin sheath surrounding nerves in the brain and spinal cord.

Global MS prevalence is also rising steadily:

  • Approximately 2.8 million cases globally in 2020
  • Around 3 million cases in 2024
  • Projected to reach 3.5 million cases by 2035

In China, patient numbers are also expected to continue increasing over the next decade.

Expanding Autoimmune Drug Innovation

The advancement of 9MW5211 reflects broader pharmaceutical industry trends toward:

  • Precision immunology
  • Targeted immune-cell depletion
  • Next-generation biologics
  • Longer-acting autoimmune therapies

Companies are increasingly focusing on therapies capable of selectively targeting disease-driving immune pathways while minimizing broader immune suppression.

Mabwell Expands Global Biopharma Presence

Mabwell is an innovation-driven biopharmaceutical company focused on oncology and aging-related diseases, with capabilities spanning:

  • Drug discovery
  • Development
  • Manufacturing
  • Commercialization

The FDA IND clearance for 9MW5211 marks an important milestone in the company’s expanding global autoimmune disease pipeline and supports its strategy of advancing first-in-class therapies targeting major unmet medical needs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!